Nkarta Announces Integrated Safety Results From 40 Patients Treated With NKX019, Allogeneic, Off-The-Shelf, CD19-Directed CAR NK Cell Therapy Candidate In Ongoing Ntrust Clinical Trial Program
Benzinga Newsdesk 4 hours ago
News
No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or
- No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus-host disease (GvHD) across 40 patients treated across five indications in the Ntrust program.
- No deaths and no treatment discontinuations due to adverse events.
- Grade 3 or higher treatment-emergent adverse events were primarily hematologic and attributed to lymphodepletion.
- Five patients (12.5%) had infusion-related reactions deemed associated with NKX019; all resolved within 24-48 hours and without tocilizumab.
- No increase in adverse events was observed at higher doses.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced integrated safety results from 40 patients treated with NKX019, an allogeneic, off-the-shelf, CD19-directed CAR NK cell therapy candidate in its ongoing Ntrust clinical trial program.
The findings were presented today in an oral presentation at the American College of Rheumatology (ACR) Convergence 2026 in Orlando by Guillermo J. Valenzuela, M.D., of Integral Rheumatology and Immunology Specialists in Plantation, Florida. The data cutoff was September 18, 2026. The cumulative safety analysis included patients with systemic sclerosis, myositis, lupus nephritis, rheumatoid arthritis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
There were no deaths and no treatment discontinuations due to adverse events. There were no reported cases of CRS of any grade, ICANS, IEC-HS or GvHD. No cases of leukoencephalopathy, a neurotoxicity associated with fludarabine, have been reported to date.